TenSixty BioSciences

Executive Summary

TenSixty BioSciences is a San Diego-based biotechnology company founded in 2021 that integrates a biology-first approach with advanced cell models, high-throughput technologies, and machine learning to discover novel antibody targets on cancer cells. The company aims to develop more effective oncology therapeutics by leveraging its interdisciplinary team to translate research from bench to bedside. While still in early stages with no disclosed funding or pipeline details, TenSixty’s focus on AI-driven antibody discovery positions it in a competitive but rapidly evolving space. The company’s private status and lack of financial disclosures suggest it is likely pre-clinical or early preclinical, with a need for capital to advance its platform and candidate programs. The management’s emphasis on a biology-first approach differentiates it from purely computational platforms, potentially offering higher-quality targets. However, without publicly available data on specific programs or validated hits, assessing its technical risk and differentiation remains challenging. If successful, TenSixty could contribute to the growing field of AI-enabled antibody discovery, though it faces significant competition from established players and other startups. The company’s location in San Diego, a major biotech hub, provides access to talent and partnerships. Overall, TenSixty BioSciences represents a high-risk, high-reward early-stage opportunity that warrants monitoring for upcoming milestones such as funding rounds or preclinical data.

Upcoming Catalysts (preview)

• Q1 2027Series A Funding Announcement70% success
• Q4 2026Lead Program Preclinical Proof-of-Concept Data50% success
• H2 2026Strategic Partnership with Pharma or CRO40% success